FDA approves Cipla’s HIV-1 generic

4/5/2017

MUMBAI, India — Cipla received Food and Drug Administration approval for its Abbreviated New Drug Application for Abacavir and Lamivudine Tablets USP, 600 mg/300 mg, from the Abacavir and Lamivudine Tablets USP, 600 mg/300 mg, are AB-rated generic equivalents to the reference listed drug, Epzicom Tablets, 600 mg/300 mg of ViiV Healthcare and are indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection.


Epzicom Tablets had sales of approximately $346.3 million for the 12-month period ended February 2017, according to IMS Health. 


X
This ad will auto-close in 10 seconds